<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701424</url>
  </required_header>
  <id_info>
    <org_study_id>RG97920</org_study_id>
    <nct_id>NCT04701424</nct_id>
  </id_info>
  <brief_title>Closed-loop in Adults With T2D Not Requiring Dialysis</brief_title>
  <acronym>AP-Renal</acronym>
  <official_title>An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery in Comparison With Standard Care in Adults With Type 2 Diabetes Not Requiring Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the efficacy, safety and utility of fully&#xD;
      automated closed-loop glucose control in the home setting over an 8 week period in adults&#xD;
      with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop&#xD;
      systems that have been performed in Cambridge in adults with type 1 diabetes in the home&#xD;
      setting, and in adults with type 2 diabetes in the inpatient setting.&#xD;
&#xD;
      This is an open-label, single centre, randomised, cross-over study, involving two home study&#xD;
      periods during which glucose levels will be controlled either by a fully automated&#xD;
      closed-loop system or by participants' usual insulin therapy in random order. Each treatment&#xD;
      arm is 8 weeks long with a 2-4 week washout period between treatments. A total of up to 30&#xD;
      participants with T2D will be recruited through outpatient clinics to allow for 24 completed&#xD;
      participants available for assessment.&#xD;
&#xD;
      Participants will receive appropriate training by the research team on the safe use of the&#xD;
      study devices (insulin pump and continuous glucose monitoring (CGM) and closed-loop insulin&#xD;
      delivery system). Participants in the control arm will continue with standard therapy and&#xD;
      will wear a blinded CGM system.&#xD;
&#xD;
      The primary outcome is time spent with glucose levels in the target range between 3.9 and&#xD;
      10.0 mmol/L as recorded by CGM. Secondary outcomes are the time spent with glucose levels&#xD;
      above and below target, as recorded by CGM, and other CGM-based metrics in addition to&#xD;
      insulin requirements. Safety evaluation comprises the tabulation of severe hypoglycaemic&#xD;
      episodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in the target glucose range (3.9 to 10.0 mmol/l)</measure>
    <time_frame>8 week intervention period</time_frame>
    <description>Percentage of time spent with sensor glucose readings in the target range from 3.9 to 10.0mmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time spent above target glucose (10.0 mmol/l)</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Percentage of time spent with sensor glucose readings above target glucose (10.0 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Mean sensor glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hypoglycaemia (&lt;3.9 mmol/l)</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Percentage of time spent with sensor glucose readings &lt;3.9 mmol/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of glucose levels</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Standard deviation of glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation of glucose levels</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Coefficient of variation of glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent below &lt;3.0 mmol/l</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Percentage of time spent with sensor glucose readings &lt;3.0 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in significant hyperglycaemia (&gt; 20 mmol/l)</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Percentage of time with glucose levels in significant hyperglycaemia (&gt; 20 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total, basal and bolus insulin dose</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Average daily total, basal and bolus insulin requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of glucose below 3.5 mmol/l</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Area under the curve of sensor glucose readings below 3.5mmol/l</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of episodes of severe hypoglycaemia</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects experiencing severe hypoglycaemia</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency and nature of other adverse events or serious adverse events</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of time of closed-loop operation</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Utility evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of time of CGM availability</measure>
    <time_frame>8 week intervention period, both arms</time_frame>
    <description>Utility evaluation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Closed loop insulin delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 8 weeks&#xD;
The CamAPS HX closed-loop system comprises:&#xD;
Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control arm will continue to follow their current diabetes management plan for the 8 week study period. Participants will be wear a masked continuous glucose monitoring (CGM) system during the 8 week study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CamAPS HX Closed-loop</intervention_name>
    <description>The CamAPS HX closed-loop system comprises:&#xD;
Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data.</description>
    <arm_group_label>Closed loop insulin delivery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiple Daily Insulin Injections (Control)</intervention_name>
    <description>Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)</description>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or over&#xD;
&#xD;
          2. Diagnosis of type 2 diabetes using standard diagnostic practice&#xD;
&#xD;
          3. Current treatment with subcutaneous insulin&#xD;
&#xD;
          4. Screening HbA1c â‰¤ 11% (97mmol/mol) on analysis from local laboratory&#xD;
&#xD;
          5. Subject is willing to perform regular finger-prick blood glucose monitoring&#xD;
&#xD;
          6. Willingness to wear study devices&#xD;
&#xD;
          7. Literate in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical or psychological condition likely to interfere with the normal conduct of the&#xD;
             study and interpretation of the study results as judged by the investigator&#xD;
&#xD;
          2. Known or suspected allergy to insulin&#xD;
&#xD;
          3. Lack of reliable telephone facility for contact&#xD;
&#xD;
          4. Pregnancy, planned pregnancy, or breast feeding&#xD;
&#xD;
          5. Severe visual impairment&#xD;
&#xD;
          6. Severe hearing impairment&#xD;
&#xD;
          7. Medically documented allergy towards the adhesive (glue) of plasters&#xD;
&#xD;
          8. Serious skin diseases located at places of the body, which potentially are possible to&#xD;
             be used for localisation of the glucose sensor&#xD;
&#xD;
          9. Illicit drugs abuse&#xD;
&#xD;
         10. Prescription drugs abuse&#xD;
&#xD;
         11. Alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Hovorka, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman Hovorka, PhD</last_name>
    <phone>+44 (0)1223 762 862</phone>
    <email>rh347@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Hovorka, PhD</last_name>
      <phone>+44 (0)1223 762 862</phone>
      <email>rh347@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Evans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aideen Daly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Boughton, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Dr Roman Hovorka</investigator_full_name>
    <investigator_title>Professor of Metabolic Technology</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>closed-loop</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>insulin pump therapy</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

